ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/VIC/3199-Frankston-Peninsula-Health-Frankston-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
44
trial(s) found.
NCT07173751
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease (
BNT327-05
)
bispecific PD-L1/VEGFA antibody
placebo
Breast cancer
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NCT07112222
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients With Advanced Solid Tumors (
LM350-01-101
)
anti-CDH17 antibody-drug conjugate
Cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06875310
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) (
CA239-0004
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3066 - Epping - Northern Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
3844 - Traralgon - Latrobe Regional Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6027 - Joondalup - Joondalup Health Campus
NCT06841354
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011) (
2870-011
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NZ
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre
NZ.6035 - Wellington - Bowen Hospital
NCT06824467
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103) (
2870-022
)
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
NCT06819735
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (
DOMISOL
, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)
anti-CCR8 monoclonal antibody
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06770569
Advanced
Phase 1
Recruiting
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors: a Single-arm, Open, Multicenter Phase I Study (
HRS-3802-101
)
unknown drug class
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
NCT06760637
Advanced
Phase 3
Recruiting
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (
FOURLIGHT-3
)
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3199 - Frankston - Peninsula Health Frankston Hospital
3940 - Capel Sound - Rosebud Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT06730386
Advanced
Phase 1
Recruiting
A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors (
AK138D1-101
)
anti-ERBB3 antibody-drug conjugate
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06712316
Advanced
Phase 2 / Phase 3
Recruiting
A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer (
BNT327-06
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2500 - Wollongong - Cancer Care Wollongong
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
2830 - Dubbo - Dubbo Base Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4812 - Hyde Park - Icon Cancer Centre Townsville
4870 - Cairns - Cairns Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
NCT06659341
Advanced
Phase 1
cohorts full
Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors
SOS1-KRAS inhibitor
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06597721
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors (
ADCE-T02-001
)
anti-TF antibody-drug conjugate
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT06532006
Advanced
Phase 3
Recruiting
A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer (
HLX22-GC-301
)
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Cancer
Gastric cancer
HER2-positive gastric cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06393374
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery (
2870-012
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Triple-negative breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
NCT06351904
Advanced
Phase 1
Recruiting
A Phase Ⅰ, Open Label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy (
RAG-01-01
)
BCG vaccine
saRNA therapy,CDKN1A-targeting
Bladder cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NCT06345729
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004) (
1084-004
)
KRAS G12C inhibitor
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06340568
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Multi-site, Open-label Trial of BNT323/DB-1303 Versus Investigator's Choice of Chemotherapy in Previously Treated Patients With HER2- Expressing Recurrent Endometrial Cancer (
Fern-EC-01
)
anti-ERBB2 antibody-drug conjugate
Endometrial cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06312176
Advanced
Phase 3
Recruiting
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (
2870-010
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Breast cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06253130
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors (
EIK1003-001
)
PARP1-selective inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast Private Hospital
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT06063681
Advanced
Phase 1
Recruiting
Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors (
StingrayTx
)
ENPP1 inhibitor
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
NCT05952557
Curative
Phase 3
Recruiting
CAMBRIA-2
: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
selective estrogen receptor degrader
selective estrogen receptor modulator
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2500 - Wollongong - Wollongong Hospital
2576 - Bowral - Southern Highlands Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3677 - Wangaratta - Northeast Health Wangaratta
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NCT05910827
Advanced
Phase 1 / Phase 2
cohorts full
A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers (
HMBD-001-103
)
anti-EGFR monoclonal antibody
anti-ERBB3 monoclonal antibody,third generation
taxane
Squamous non-small-cell lung cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05694936
Advanced
Phase 2
Recruiting
A Phase II Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (
VADER
Study).
HDAC inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05640999
Radonc
Phase 2
Recruiting
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER) (
EN10
)
Radiotherapy
cancer therapy
Endometrial cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05611931
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (
XPORT-EC-042
)
XPO1 inhibitor
placebo
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - ICON Cancer Care
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05607498
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma (
EMB07X101
)
bispecific T-cell engager,ROR1-targeting
Lymphoma
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - One Clinical Research
NCT05598151
Advanced
Phase 1
Recruiting
A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM97662 as a Single Agent in Patients With Advanced or Metastatic Solid Tumors (
HM-EZHI-101
)
EZH1/2 inhibitor
Solid tumour
VIC
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05413421
Advanced
Phase 1
Recruiting
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer (
ORIC-944-01
)
PRC2 complex inhibitor
Prostate cancer
NSW
2076 - Wahroonga - Sydney Adventist Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
NCT05267626
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer (
CP-AU-007-01
)
anti-IL-2 monoclonal antibody
Cancer
Cutaneous melanoma
Non-small cell lung cancer
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05215340
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (
TROPION-Lung08
)
anti-PD-1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05205109
Advanced
Phase 1
Recruiting
A Phase I/Ib, Multi-center, Open-label, and Dose-finding Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG-037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors (
ATG-037-001
)
CD73 inhibitor
anti-PD-1 monoclonal antibody
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - One Clinical Research
NCT05155332
Advanced
Phase 1
Recruiting
Phase I Open-label, Dose Escalation Trial of BI 1831169 Monotherapy and in Combination With an Anti-PD-1 mAb in Patients With Advanced or Metastatic Solid Tumors (
1456-0001
)
oncolytic virus
Solid tumour
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05006716
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies (
CaDAnCe-101
)
BTK PROTAC degrader
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
NSW
2139 - Concord - Concord Repatriation General Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT04956640
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (
LOXO-RAS-20001
)
KRAS G12C inhibitor
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04879329
Advanced
Phase 2
Recruiting
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2 (
RC48G001
)
anti-ERBB2 antibody-drug conjugate
anti-PD-1 monoclonal antibody
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
ACTRN12625000779471
Advanced
Phase 1 / Phase 2
Not yet recruiting
A Phase I/IIa Study of EGFR-targeted EDVs Carrying Doxorubicin (E-EDV-Dox) Combined with EDVs Carrying a-Galactosyl Ceramide (EDV-GC) in People with Recurrent Glioblastoma. (
ENG20
)
anthracycline
Glioblastoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12621000273886
Curative
Phase 2
Recruiting
The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer -
ADELE
: a randomised phase 2 trial
anti-PD-1 monoclonal antibody
Endometrial cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0110 - Whangarei - Whangarei Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (41)
cohorts full (2)
Not yet recruiting (1)
Recruitment Country and State
VIC (44)
NSW (37)
SA (23)
QLD (21)
WA (16)
NZ (7)
ACT (3)
TAS (1)
Phase
Phase 1 (14)
Phase 1 / Phase 2 (10)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (14)
Trial Type
Advanced (39)
Curative (3)
Radonc (1)
Haem (1)
Cancer Therapy Class
PD-1/PD-L1
41%
PD-1
34%
Trop2
14%
ERBB2
14%
PD-L1
11%
KRAS
11%
KRAS G12C
11%
EGFR
9%
VEGFA
7%
CDK4
7%
CDK6
7%
oestrogen axis
7%
ERBB3
5%
ER
5%
CDH17
2%
VEGF
2%
CCR8
2%
CDK4 selective
2%
HRAS G12C
2%
NRAS G12C
2%
TF
2%
CDKN1A
2%
DPD
2%
orotate phosphoribosyltransferase
2%
PARP
2%
PARP1-selective
2%
ENPP1
2%
HDAC
2%
XPO1
2%
ROR1
2%
EZH1
2%
EZH2
2%
AR
2%
CYP17A1
2%
PRC2 complex
2%
androgen axis
2%
IL-2
2%
CD73
2%
BTK
2%
AKT
2%
CDK7
2%
PI3Kalpha
2%
mTOR
2%
mTORC1
2%
Facility
3199 - Frankston - Peninsula Health Frankston Hospital (44)
2109 - North Ryde - Macquarie University Hospital (10)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (10)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (9)
3168 - Clayton - Monash Medical Centre (8)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (7)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
6009 - Nedlands - Linear Clinical Research (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (6)
4102 - Woolloongabba - Princess Alexandra Hospital (5)
6009 - Nedlands - One Clinical Research (5)
5042 - Bedford Park - Flinders Medical Centre (5)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (4)
2065 - St Leonards - GenesisCare North Shore Private Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
3004 - Melbourne, Southbank - Alfred Health (4)
2500 - Wollongong - Cancer Care Wollongong (3)
2605 - Garran - The Canberra Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
2139 - Concord - Concord Repatriation General Hospital (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
5000 - South Australia - GenesisCare St Andrews Hospital (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
4120 - Greenslopes - Greenslopes Private Hospital (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
4870 - Cairns - Cairns Base Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2500 - Wollongong - Wollongong Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
3121 - Richmond - Epworth Freemasons Hospital (2)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (2)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3066 - Epping - Northern Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
NZ.0627 - Epsom - Mercy Ascot Hospital's Harbour Cancer & Wellness Centre (1)
NZ.6035 - Wellington - Bowen Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
3940 - Capel Sound - Rosebud Hospital (1)
2830 - Dubbo - Dubbo Base Hospital (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4215 - Southport - Gold Coast Private Hospital (1)
NA
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2576 - Bowral - Southern Highlands Cancer Centre (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3630 - Shepparton - Goulburn Valley Health (1)
3677 - Wangaratta - Northeast Health Wangaratta (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4215 - Southport - ICON Cancer Care (1)
4350 - Toowoomba - Toowoomba Hospital (1)
7000 - Hobart - Royal Hobart Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
4217 - Benowa - Pindara Private Hospital (1)
6005 - West Perth - Sir Charles Gairdner Hospital / Western Heamatology and Oncology Clinics (1)
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare (1)
2060 - North Sydney - Mater Hospital (1)
NZ.0110 - Whangarei - Whangarei Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
Cancer Type
Cancer
Solid tumour
Thoracic cancer
Breast cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Gastrointestinal cancer
Breast adenocarcinoma
Gynaecological cancer
Upper gastrointestinal cancer
Triple-negative breast cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Endometrial cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Pancreatobiliary cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Haematological malignancy
Lymphoma
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Gastric adenocarcinoma
HER2-positive gastric cancer
Biliary tract cancer
Hepatobiliary cancer
Bladder cancer
Colorectal adenocarcinoma
HER2-low breast cancer
HER2-negative breast cancer
HER2-positive breast cancer
Squamous non-small-cell lung cancer
Male genital cancers
Prostate cancer
Cutaneous melanoma
Melanoma
Skin cancer
B-cell lymphoma
B-cell malignancy
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
High-grade B-cell lymphoma
Leukaemia
Lymphoid leukaemia
Mantle cell lymphoma
Marginal zone lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
Urothelial carcinoma
ER-positive breast cancer
HR-positive breast cancer
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Kidney cancer
Mesothelioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy